TY - JOUR
T1 - Neural correlates of delay discount alterations in addiction and psychiatric disorders
T2 - A systematic review of magnetic resonance imaging studies
AU - Noda, Yoshihiro
AU - Barr, Mera S.
AU - ElSalhy, Muhammad
AU - Masuda, Fumi
AU - Tarumi, Ryosuke
AU - Ogyu, Kamiyu
AU - Wada, Masataka
AU - Tsugawa, Sakiko
AU - Miyazaki, Takahiro
AU - Nakajima, Shinichiro
AU - Mimura, Masaru
N1 - Funding Information:
YN has received a Grant-in-Aid for Young Scientists (KAKENHI), a research grant from Japan Agency for Medical Research and development (AMED) , an investigator-initiated clinical study grant from TEIJIN PHARMA LIMITED . YN also receives research grants from Japan Health Foundation , Meiji Yasuda Mental Health Foundation , Mitsui Life Social Welfare Foundation , Takeda Science Foundation , SENSHIN Medical Research Foundation , Health Science Center Foundation , Mochida Memorial Foundation for Medical and Pharmaceutical Research , and Daiichi Sankyo Scholarship Donation Program . He has received research supports from Otsuka Pharmaceutical , Shionogi , and Meiji Seika Pharma . YN also receives equipment-in-kind supports for an investigator-initiated study from Magventure Inc., Inter Reha Co., Ltd. , Rogue Resolutions Ltd. , and Miyuki Giken Co., Ltd . SN has received research support from Japan Society for the Promotion of Science (Grant-in-Aid for Young Scientists A, Grants-in-Aid for Scientific Research B, and Grants-in-Aid for Scientific Research C), Japan Agency for Medical Research and development (AMED), Japan Research Foundation for Clinical Pharmacology , Naito Foundation , Uehara Memorial Foundation , Takeda Science Foundation , Daiichi Sankyo Research Program , and Novartis Research Program , manuscript fees or speaker's honoraria from Meiji-Seika Pharma , Otsuka Pharmaceutical , Dainippon-Sumitomo Pharma and Yoshitomi Yakuhin within the past three years. MM has received grants or speaker's honoraria from Asahi Kasei Pharma , Astellas Pharmaceutical , Daiichi Sankyo , Dainippon-Sumitomo Pharma , Eisai , Eli Lilly , GlaxoSmithKline , Janssen Pharmaceutical , Meiji-Seika Pharma , Mochida Pharmaceutical , MSD , Novartis Pharma , Otsuka Pharmaceutical , Pfizer , Shionogi , Takeda , Tanabe Mitsubishi Pharma , and Yoshitomi Yakuhin within 3 years. Other authors have no financial or other relationship relevant to the subject of this manuscript.
Funding Information:
YN has received a Grant-in-Aid for Young Scientists (KAKENHI), a research grant from Japan Agency for Medical Research and development (AMED), an investigator-initiated clinical study grant from TEIJIN PHARMA LIMITED. YN also receives research grants from Japan Health Foundation, Meiji Yasuda Mental Health Foundation, Mitsui Life Social Welfare Foundation, Takeda Science Foundation, SENSHIN Medical Research Foundation, Health Science Center Foundation, Mochida Memorial Foundation for Medical and Pharmaceutical Research, and Daiichi Sankyo Scholarship Donation Program. He has received research supports from Otsuka Pharmaceutical, Shionogi, and Meiji Seika Pharma. YN also receives equipment-in-kind supports for an investigator-initiated study from Magventure Inc., Inter Reha Co., Ltd., Rogue Resolutions Ltd., and Miyuki Giken Co., Ltd. SN has received research support from Japan Society for the Promotion of Science (Grant-in-Aid for Young Scientists A, Grants-in-Aid for Scientific Research B, and Grants-in-Aid for Scientific Research C), Japan Agency for Medical Research and development (AMED), Japan Research Foundation for Clinical Pharmacology, Naito Foundation, Uehara Memorial Foundation, Takeda Science Foundation, Daiichi Sankyo Research Program, and Novartis Research Program, manuscript fees or speaker's honoraria from Meiji-Seika Pharma, Otsuka Pharmaceutical, Dainippon-Sumitomo Pharma and Yoshitomi Yakuhin within the past three years. MM has received grants or speaker's honoraria from Asahi Kasei Pharma, Astellas Pharmaceutical, Daiichi Sankyo, Dainippon-Sumitomo Pharma, Eisai, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceutical, Meiji-Seika Pharma, Mochida Pharmaceutical, MSD, Novartis Pharma, Otsuka Pharmaceutical, Pfizer, Shionogi, Takeda, Tanabe Mitsubishi Pharma, and Yoshitomi Yakuhin within 3 years. Other authors have no financial or other relationship relevant to the subject of this manuscript.
Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2020/4/20
Y1 - 2020/4/20
N2 - Delay discounting (DD) represents decreased subjective value for delayed reward relative to the same reward at present. The concept of DD has been applied for pathophysiology of addiction and psychiatric disorders. However, the detailed neuroimaging correlates of DD underlying pathophysiology still remain unclear. Thus, we conducted a systematic review to investigate neural correlates of DD on magnetic resonance imaging studies among addiction and psychiatric disorders. Specific search terms were set on PubMed to identify relevant articles. Initial search identified 551 records and 31 studies met the inclusion criteria. The present review revealed that greater DD was correlated with increased activity in areas related to reward evaluation and prediction as well as decreased activity in areas related to cognitive control. Healthy controls showed smaller changes in activities of these areas associated with DD when compared to patient groups. As the neural basis related to DD, three neural networks have been proposed that are associated with the actions of short-term interests and long-term benefits. Among the three potential neural networks on DD, the first one included the ventromedial prefrontal cortex and ventral striatum and implicated in evaluating reward values, the second network included the anterior cingulate cortex and linked to cognitive control, and the third network included the middle temporal gyrus and was involved in predictions and affection. This review generated consistent findings on the neural basis of DD among patients with addiction and psychiatric disorders, which may represent the pathophysiology related to DD and impulsivity of mental illness.
AB - Delay discounting (DD) represents decreased subjective value for delayed reward relative to the same reward at present. The concept of DD has been applied for pathophysiology of addiction and psychiatric disorders. However, the detailed neuroimaging correlates of DD underlying pathophysiology still remain unclear. Thus, we conducted a systematic review to investigate neural correlates of DD on magnetic resonance imaging studies among addiction and psychiatric disorders. Specific search terms were set on PubMed to identify relevant articles. Initial search identified 551 records and 31 studies met the inclusion criteria. The present review revealed that greater DD was correlated with increased activity in areas related to reward evaluation and prediction as well as decreased activity in areas related to cognitive control. Healthy controls showed smaller changes in activities of these areas associated with DD when compared to patient groups. As the neural basis related to DD, three neural networks have been proposed that are associated with the actions of short-term interests and long-term benefits. Among the three potential neural networks on DD, the first one included the ventromedial prefrontal cortex and ventral striatum and implicated in evaluating reward values, the second network included the anterior cingulate cortex and linked to cognitive control, and the third network included the middle temporal gyrus and was involved in predictions and affection. This review generated consistent findings on the neural basis of DD among patients with addiction and psychiatric disorders, which may represent the pathophysiology related to DD and impulsivity of mental illness.
KW - Behavioral economics
KW - Cognitive control
KW - Delay discount
KW - Prediction and affection
KW - Reward value
UR - http://www.scopus.com/inward/record.url?scp=85078444379&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078444379&partnerID=8YFLogxK
U2 - 10.1016/j.pnpbp.2019.109822
DO - 10.1016/j.pnpbp.2019.109822
M3 - Review article
C2 - 31751662
AN - SCOPUS:85078444379
SN - 0278-5846
VL - 99
JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry
JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry
M1 - 109822
ER -